Computer-designed vaccine elicits potent antibodies against RSV

Medical Xpress | March 07, 2019

A first-of-its-kind nanoparticle vaccine candidate for the respiratory syncytial virus has been designed in an international research effort. RSV is second only to malaria as a cause of infant mortality worldwide. The new vaccine elicits potent neutralizing antibodies against RSV in both mice and monkeys. The animal research findings, reported March 7 in the journal Cell, pave the way for human clinical trials. RSV infects nearly all children by the age of three. Infection typically causes mild symptoms but can be more serious in newborns, immunocompromised individuals and the elderly. In the United States, RSV is the leading cause of pneumonia in babies under a year old. According to the National Institute for Allergy and Infectious Disease, RSV is responsible for an estimated 64 million infections and causes 160,000 deaths globally each year. About 99 percent of RSV deaths occur in developing countries. After considerable research, several vaccine candidates are in preclinical or clinical testing. As yet no RSV vaccine is ready for use in disease prevention.

Spotlight

Industrializing cell therapies is a new arena, and speed is critical. To help you realize your commercialization timeline, GE Healthcare’s Life Sciences solutions have expanded beyond biopharmaceutical manufacturing. Enterprise Solutions for Cell Therapy provides you with access to our end-to-end ecosystem of next-generation equipment, turnkey manufacturing solutions, and comprehensive services.

Spotlight

Industrializing cell therapies is a new arena, and speed is critical. To help you realize your commercialization timeline, GE Healthcare’s Life Sciences solutions have expanded beyond biopharmaceutical manufacturing. Enterprise Solutions for Cell Therapy provides you with access to our end-to-end ecosystem of next-generation equipment, turnkey manufacturing solutions, and comprehensive services.

Related News

MEDICAL

Nanoform Launches Technology that can form Biological Nanoparticles as Small as 50 nm and New Near-Term Business Target for 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle formation technology gives want to improving the potential outcomes and probabilities of growing better medications for patients and it extends Nanoform's reach into the growing biological market. The technology is in its beginning phases of advancement and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side notwithstanding the eight CESS® little atom nanoparticle innovation non-GMP lines.

Read More

miniPCR bio Announces Launch of the GELATO™ an Integrated DNA Analysis System

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durability and affordability its broad range of users demand. "Our users were asking for a tool that integrates the capabilities of professional lab instruments with the ease of use and compact size of our educational tools," said Dr. Ezequiel Alvarez Saavedra, co-founder of miniPCR bio. "GELATO™ answers that call." Despite a small footprint, GELATO™'s range of casting options allows users to process up to 50 nucleic acid samples at a time. Its variable voltage built-in power supply allows for fast separation of DNA, and its integrated blue-light transilluminator makes it safe for use in all settings. GELATO™ includes a cell-phone compatible documentation hood and features a built-in cutting tray for direct gel excision.

Read More

CELL AND GENE THERAPY

TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantation and a chemosensitizer in hematological and solid tumors. It can also be used for stem cell collection in healthy individuals for personalized regenerative medicine. Taigexyn® is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide. Apart from upfront fees, TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments.

Read More